Development, implementation and evaluation of Educational tools and Decision Aids for immune checkpoint-inhibitors in advanced LUng cancer: a mixed-methods Study (DEDALUS) / Part II: Evaluation

Development, implementation and evaluation of Educational tools and Decision Aids for immune checkpoint-inhibitors in advanced LUng cancer: a mixed-methods Study (DEDALUS) / Part II: Evaluation - DEDALUS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00035861

Enrollment

Registered

2025-03-10

Start date

2025-03-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Patients with advanced lung cancer eligible for or during immunotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients being treated at the Department of Thoracic Oncology in Heidelberg with metastatic lung cancer (stage IV, palliative treatment goal) and the indication to receive immunotherapy or under treatment with immunotherapy, with sufficient command of German, being able to fill in the questionnaires.

Exclusion criteria

Exclusion criteria: Patients not able or willing to give consent.

Design outcomes

Primary

Measure	Time frame
- Decisional conflict (Decisional Conflict Scale; DCS) (Buchholz, Hölzel, Kriston, Simon, & Härter, 2011; O'Connor, 1995) - Knowledge regarding treatment (focus on immunotherapy) and decision-making (knowledge test developed on the basis of work by Petrillo et al. (Petrillo et al., 2025; Petrillo et al., 2021), Savelberg et al. (Savelberg et al., 2015) , and a sample tool available from https://decisionaid.ohri.ca/docs/develop/Tools/Knowledge_Tamoxifen.pdf)	—

Measure

Time frame

- Decisional conflict (Decisional Conflict Scale; DCS) (Buchholz, Hölzel, Kriston, Simon, & Härter, 2011; O'Connor, 1995) - Knowledge regarding treatment (focus on immunotherapy) and decision-making (knowledge test developed on the basis of work by Petrillo et al. (Petrillo et al., 2025; Petrillo et al., 2021), Savelberg et al. (Savelberg et al., 2015) , and a sample tool available from https://decisionaid.ohri.ca/docs/develop/Tools/Knowledge_Tamoxifen.pdf)

—

Secondary

Measure	Time frame
- Preparedness for decision-making (PDMS) (Bennett et al., 2010; Buchholz, Simon, & Härter, 2011; Härter et al., 2011) - Decisional Self-efficacy scale (Bunn & O'Connor, 1996; Song & Sereika, 2006) - Decision making type as proposed in previous work of the research group (Deis et al., 2023; Villalobos et al., 2024)	—

Countries

Germany

Contacts

Public ContactMatthias Villalobos

Universitätsklinikum Thoraxklinik Heidelberg

matthias.villalobos@med.uni-heidelberg.de062213968042

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026